Back to top
more

Coloplast A/S Sponsored ADR (CLPBY)

(Delayed Data from OTC)

$12.22 USD

12.22
48,039

-0.06 (-0.49%)

Updated May 13, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for CLPBY

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Coloplast AS Sponsored ADR falls in the month of September.

All items in Millions except Per Share data.

9/30/2023 9/30/2022 9/30/2021 9/30/2020 9/30/2019
Assets          
Cash & Equivalents 131 92 108 88 101
Receivables 734 679 598 528 541
Notes Receivable 0 0 0 0 0
Inventories 505 465 390 335 292
Other Current Assets 55 43 28 24 27
Total Current Assets 1,425 1,279 1,124 975 961
Net Property & Equipment 736 652 608 497 491
Investments & Advances 9 7 7 4 1
Other Non-Current Assets 6 5 4 4 4
Deferred Charges 127 98 119 100 89
Intangibles 4,482 2,956 587 355 378
Deposits & Other Assets 0 0 0 0 0
Total Assets 6,906 5,097 2,546 2,028 1,924
Liabilities & Shareholders Equity 9/30/2023 9/30/2022 9/30/2021 9/30/2020 9/30/2019
Notes Payable 0 0 0 0 0
Accounts Payable 186 181 166 122 130
Current Portion Long-Term Debt 695 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 606 196 149 151 161
Other Current Liabilities 819 662 671 444 454
Total Current Liabilities 2,339 1,070 1,015 748 747
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 1,657 2,385 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 334 361 146 103 112
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 4,425 3,888 1,233 915 879
Shareholders Equity 9/30/2023 9/30/2022 9/30/2021 9/30/2020 9/30/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 33 31 35 32 33
Capital Surplus 0 0 0 0 0
Retained Earnings 2,098 785 869 712 661
Other Equity 350 392 409 368 351
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 2,481 1,209 1,313 1,112 1,045
Total Liabilities & Shareholder's Equity 6,906 5,097 2,546 2,028 1,924
Total Common Equity 2,481 1,209 1,313 1,112 1,045
Shares Outstanding NA NA 2,160.00 2,160.00 2,160.00
Book Value Per Share -0.02 -0.01 0.61 0.51 0.48

Fiscal Year End for Coloplast AS Sponsored ADR falls in the month of September.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 132 131 125 93
Receivables NA 757 734 715 688
Notes Receivable NA 0 0 0 0
Inventories NA 508 505 520 506
Other Current Assets NA 57 55 54 57
Total Current Assets NA 1,454 1,425 1,413 1,343
Net Property & Equipment NA 756 736 722 690
Investments & Advances NA 9 9 10 10
Other Non-Current Assets NA 5 6 5 5
Deferred Charges NA 132 127 97 95
Intangibles NA 4,540 4,482 2,755 2,825
Deposits & Other Assets NA 0 0 0 0
Total Assets NA 7,017 6,906 5,126 5,087
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 168 186 156 164
Current Portion Long-Term Debt NA 700 695 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 668 606 221 195
Other Current Liabilities NA 1,163 819 1,028 970
Total Current Liabilities NA 2,732 2,339 1,437 1,359
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 1,668 1,657 2,394 2,361
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 334 248 258
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 4,832 4,425 4,178 4,073
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 33 33 32 31
Capital Surplus NA 0 0 0 0
Retained Earnings NA 2,301 2,098 1,151 947
Other Equity NA -150 350 -234 35
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 2,184 2,481 948 1,014
Total Liabilities & Shareholder's Equity NA 7,017 6,906 5,126 5,087
Total Common Equity 0 2,184 2,481 948 1,014
Shares Outstanding NA NA NA NA NA
Book Value Per Share 0.00 -0.02 -0.02 -0.01 -0.01